XCSE
EMBLA
Market cap1.83bUSD
May 03, Last price
29.50DKK
Name
Ossur hf
Chart & Performance
Profile
Össur hf., together with its subsidiaries, designs, develops, produces, and sells non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It offers prosthetics products, including artificial limbs and related products for amputees; and lower and upper limb prosthetic components, including feet, knees, hands, fingers, liners, and other components. The company also provides bracing and supports products, such as supporting devices for spinal, knee, hip, foot, ankle, and hands that are primarily used to support joints and other body parts for therapeutic and preventative purposes; and injury solutions to enhance the healing process of bone and soft tissue injuries. It serves specialized healthcare providers, including orthopedic and prosthetic clinics, hospitals, and surgery centers. The company sells its products through its direct sales networks and distributors. Össur hf. was founded in 1971 and is headquartered in Reykjavik, Iceland. Össur hf. is a subsidiary of William Demant Invest A/S.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||||
Revenues | 854,889 8.81% | 785,683 9.33% | 718,650 0.00% | |||||||
Cost of revenue | 742,136 | 698,223 | 678,670 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 112,753 | 87,460 | 39,980 | |||||||
NOPBT Margin | 13.19% | 11.13% | 5.56% | |||||||
Operating Taxes | 21,603 | 17,206 | 12,962 | |||||||
Tax Rate | 19.16% | 19.67% | 32.42% | |||||||
NOPAT | 91,150 | 70,254 | 27,018 | |||||||
Net income | 68,278 16.94% | 58,389 37.34% | 42,513 -33.57% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | (9,941) | |||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 52,756 | 43,325 | 86,837 | |||||||
Long-term debt | 589,448 | 558,805 | 394,085 | |||||||
Deferred revenue | 8,589 | 7,277 | 6,042 | |||||||
Other long-term liabilities | 55,882 | 24,017 | 139,497 | |||||||
Net debt | 556,041 | 504,415 | 386,821 | |||||||
Cash flow | ||||||||||
Cash from operating activities | 116,066 | 94,324 | 60,771 | |||||||
CAPEX | (39,227) | (42,278) | (25,942) | |||||||
Cash from investing activities | (104,770) | (57,147) | (66,261) | |||||||
Cash from financing activities | 5,761 | (40,959) | 3,789 | |||||||
FCF | 62,624 | 22,973 | 21,597 | |||||||
Balance | ||||||||||
Cash | 86,163 | 72,653 | 76,631 | |||||||
Long term investments | 25,062 | 17,470 | ||||||||
Excess cash | 43,419 | 58,431 | 58,168 | |||||||
Stockholders' equity | 767,454 | 643,528 | 574,080 | |||||||
Invested Capital | 1,301,540 | 1,145,601 | 1,076,414 | |||||||
ROIC | 7.45% | 6.32% | 2.57% | |||||||
ROCE | 8.16% | 7.09% | 3.42% | |||||||
EV | ||||||||||
Common stock shares outstanding | 426,659 | 420,318 | 417,831 | |||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | 168,726 | 137,380 | 89,345 | |||||||
EV/EBITDA | ||||||||||
Interest | 23,248 | 20,720 | 12,947 | |||||||
Interest/NOPBT | 20.62% | 23.69% | 32.38% |